Overexpression of LGR-5 as a Predictor of Poor Outcome in Patients with Hepatocellular Carcinoma
Abstract
:1. Introduction
2. Patients and Methods
2.1. Patients
2.2. IHC and Scoring
2.3. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. LGF-5 Expression
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Hung, T.H.; Liang, C.M.; Hsu, C.N.; Tai, W.C.; Tsai, K.L.; Ku, M.K.; Wang, J.W.; Tseng, K.L.; Yuan, L.T.; Nguang, S.H.; et al. Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan. PLoS ONE 2017, 12, e0181858. [Google Scholar] [CrossRef]
- Kim, G.A.; Lee, H.C.; Choe, J.; Kim, M.J.; Lee, M.J.; Chang, H.S.; Bae, I.Y.; Kim, H.K.; An, J.; Shim, J.H.; et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J. Hepatol. 2017. [Google Scholar] [CrossRef] [PubMed]
- Huang, Y.T.; Yang, H.I.; Liu, J.; Lee, M.H.; Freeman, J.R.; Chen, C.J. Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk. Epidemiology 2016, 27, 14–20. [Google Scholar] [CrossRef] [PubMed]
- Wu, M.Y.; Yiang, G.T.; Cheng, P.W.; Chu, P.Y.; Li, C.J. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. J. Clin. Med. 2018, 7, 213. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Y.; Wang, B.; Wu, J.; Zhang, C.; Zhou, Y.; Yang, X.R.; Zhou, J.; Guo, W.; Fan, J. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer 2016, 16, 506. [Google Scholar] [CrossRef] [PubMed]
- Yu, G.P.; Xiao, Q.Y.; Shi, Z.Q.; Tang, L.S.; Ma, X.P.; Zhang, L.Y.; Chen, H.T.; Wang, W.J.; Zhang, P.Y.; Ding, D.L.; et al. Genetic polymorphisms in apoptosis-related genes and the prognosis of hepatocellular carcinoma. Am. J. Cancer Res. 2015, 5, 3249–3259. [Google Scholar] [PubMed]
- Cai, J.; Li, B.; Zhu, Y.; Fang, X.; Zhu, M.; Wang, M.; Liu, S.; Jiang, X.; Zheng, J.; Zhang, X.; et al. Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine 2017, 19, 18–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, B.N.; Chu, I.S. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma. Exp. Mol. Med. 2018, 50, e418. [Google Scholar] [CrossRef] [PubMed]
- Ko, C.J.; Li, C.J.; Wu, M.Y.; Chu, P.-Y. Overexpression of Epithelial Cell Adhesion Molecule as a Predictor of Poor Outcome in Patients with Hepatocellular Carcinom. Exp. Ther. Med. 2018, 16, 4810–4816. [Google Scholar] [CrossRef] [PubMed]
- Al-Kharusi, M.R.; Smartt, H.J.; Greenhough, A.; Collard, T.J.; Emery, E.D.; Williams, A.C.; Paraskeva, C. LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: Implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis 2013, 34, 1150–1157. [Google Scholar] [CrossRef] [PubMed]
- McClanahan, T.; Koseoglu, S.; Smith, K.; Grein, J.; Gustafson, E.; Black, S.; Kirschmeier, P.; Samatar, A.A. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol. Ther. 2006, 5, 419–426. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanese, K.; Fukuma, M.; Yamada, T.; Mori, T.; Yoshikawa, T.; Watanabe, W.; Ishiko, A.; Amagai, M.; Nishikawa, T.; Sakamoto, M. G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am. J. Pathol. 2008, 173, 835–843. [Google Scholar] [CrossRef] [PubMed]
- Hou, M.F.; Chen, P.M.; Chu, P.Y. LGR5 overexpression confers poor relapse-free survival in breast cancer patients. BMC Cancer 2018, 18, 219. [Google Scholar] [CrossRef] [PubMed]
- Becker, L.; Huang, Q.; Mashimo, H. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett’s esophagus and esophageal adenocarcinoma. Diseases Esophagus 2010, 23, 168–174. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.L.; Chen, P.M.; Lin, P.Y.; Hsiau, Y.T.; Chu, P.Y. ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of Elderly Patients. Anticancer Res. 2016, 36, 2983–2988. [Google Scholar] [PubMed]
- Yu, H.C.; Hung, M.H.; Chen, Y.L.; Chu, P.Y.; Wang, C.Y.; Chao, T.T.; Liu, C.Y.; Shiau, C.W.; Chen, K.F. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Disease 2014, 5, e1359. [Google Scholar] [CrossRef] [PubMed]
- Cao, H.Z.; Liu, X.F.; Yang, W.T.; Chen, Q.; Zheng, P.S. LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer. Cell Death Disease 2017, 8, e3039. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Yu, G.Z.; Cheng, X.K.; Li, X.D.; Zeng, X.T.; Ren, X.Q. LGR5 promotes hepatocellular carcinoma metastasis through inducting epithelial-mesenchymal transition. Oncotarget 2017, 8, 50896–50903. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, W.; Fu, Q.; Fang, F.; Fang, J.; Zhang, Q.; Hong, Y. Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 predicts poor prognosis in hepatocellular carcinoma. Saudi J. Biol. Sci. 2017. [Google Scholar] [CrossRef] [PubMed]
Variables | Total | LGR-5 | p-Value | |
---|---|---|---|---|
Low Expression | High Expression | |||
Age (years) | 63.0 ± 11.9 | 63.3 ± 12.2 | 62.6 ± 11.6 | 0.935 |
Gender, n | ||||
Female | 70 | 35 | 35 | 0.506 |
Male | 282 | 128 | 154 | |
Recurrence, n | ||||
Negative | 291 | 135 | 156 | 1.000 |
Positive | 61 | 28 | 33 | |
Differentiation, n | ||||
Well/ Moderate | 168 | 92 | 76 | 0.003 |
Poor | 184 | 71 | 113 | |
Clinical stage, n | ||||
Stage I, II | 276 | 127 | 149 | 0.897 |
Stage III, IV | 76 | 36 | 40 | |
Tumor size, (mm) | 54.4 ± 46.0 | 56.5 ± 47.7 | 52.6 ± 44.7 | 0.319 |
Child–Pugh score | 5.23 ± 0.73 | 5.21 ± 0.65 | 5.24 ± 0.78 | 0.545 |
Survival days | 809.1 ± 418.7 | 800.1 ± 396.7 | 816.8 ± 437.9 | 0.029 |
Survive, n | 298 | 146 | 152 | 0.018 |
Hepatitis B, n | ||||
Negative | 167 | 77 | 90 | 1.000 |
Positive | 185 | 86 | 99 | |
Hepatitis C, n | ||||
Negative | 235 | 104 | 131 | 0.308 |
Positive | 117 | 59 | 58 |
Variables | Number | Overall Survival | Log-Rank | |
---|---|---|---|---|
Median Survival Days | Survival (%) | |||
Gender | ||||
Female | 70 | 845 | 91.4 | 0.068 |
Male | 282 | 741 | 83.3 | |
Recurrence | ||||
Negative | 291 | 804 | 90.3 | <0.001 |
Positive | 61 | 599 | 59.0 | |
Differentiation | ||||
Well/Moderate | 168 | 804 | 86.9 | 0.215 |
Poor | 184 | 736 | 83.1 | |
Clinical stage | ||||
Stage I, II | 276 | 818 | 92.0 | <0.001 |
Stage III, IV | 76 | 531 | 58.7 | |
Hepatitis B | ||||
Negative | 167 | 812 | 82.1 | 0.607 |
Positive | 185 | 740 | 83.3 | |
Hepatitis C | ||||
Negative | 235 | 732 | 82.1 | 0.463 |
Positive | 117 | 848 | 84.5 | |
LGR-5 | ||||
Low | 163 | 755 | 89.6 | 0.020 |
High | 189 | 741 | 80.9 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ko, C.-J.; Li, C.-J.; Wu, M.-Y.; Chu, P.-Y. Overexpression of LGR-5 as a Predictor of Poor Outcome in Patients with Hepatocellular Carcinoma. Int. J. Environ. Res. Public Health 2019, 16, 1836. https://doi.org/10.3390/ijerph16101836
Ko C-J, Li C-J, Wu M-Y, Chu P-Y. Overexpression of LGR-5 as a Predictor of Poor Outcome in Patients with Hepatocellular Carcinoma. International Journal of Environmental Research and Public Health. 2019; 16(10):1836. https://doi.org/10.3390/ijerph16101836
Chicago/Turabian StyleKo, Chih-Jan, Chia-Jung Li, Meng-Yu Wu, and Pei-Yi Chu. 2019. "Overexpression of LGR-5 as a Predictor of Poor Outcome in Patients with Hepatocellular Carcinoma" International Journal of Environmental Research and Public Health 16, no. 10: 1836. https://doi.org/10.3390/ijerph16101836